Myoclonus-dystonia: An update

Movement Disorders

Volumn 24, Issue 4, 2009, Pages 479-489

  Kinugawa, Kiyoka ^a,b   Vidailhet, Marie ^a,b   Clot, Fabienne ^a   Apartis, Emmanuelle ^b,c   Grabli, David ^a,b   Roze, Emmanuel ^a,b,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

Author keywords

Clinical neurology; Epsilon sarcoglycan; Genetics; Myoclonus dystonia; Pathophysiology; Primary dystonia

Indexed keywords

DOPAMINE 2 RECEPTOR; EPSILON SARCOGLYCAN; GENE PRODUCT; PROTEIN DYT1; TORSIN A; UNCLASSIFIED DRUG; SARCOGLYCAN; SGCE PROTEIN, HUMAN;

ATTENTION DEFICIT DISORDER; BASAL GANGLION; CHOREA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DYSTONIA; EEG ABNORMALITY; ELECTROMYOGRAPHY; FAMILY HISTORY; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENOME IMPRINTING; GENOTYPE PHENOTYPE CORRELATION; GLOBUS PALLIDUS; HUMAN; INHERITANCE; LABORATORY TEST; MISSENSE MUTATION; MYOCLONUS DYSTONIA; NEUROIMAGING; NEUROPHYSIOLOGY; NONSENSE MUTATION; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PATHOPHYSIOLOGY; PENETRANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPLICE SITE MUTATION; GENETICS; METHODOLOGY; MOTOR DYSFUNCTION; MUTATION; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE IMAGING;

DIAGNOSIS, DIFFERENTIAL; DYSTONIA; HUMANS; MAGNETIC RESONANCE IMAGING; MOVEMENT DISORDERS; MUTATION; MYOCLONUS; SARCOGLYCANS;

EID: 67651183916     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22425     Document Type: Review

References (104)

1. Obeso JA, Rothwell JC, Lang AE, Marsden CD. Myoclonic dystonia. Neurology 1983;33:825-830.
2. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996;11:119-124.
3. Valente EM, Edwards MJ, Mir P, et al. The epsilon-sarcoglycan gene in myoclonic syndromes. Neurology 2005;64:737:739.
4. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006;13:433-444.
5. Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008;70:1010-1016.
6. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001;29:66-69.
7. Schule B, Kock N, Svetel M, et al. Genetic heterogeneity in ten families with myoclonus-dystonia. J Neurol Neurosurg Psychiatry 2004;75:1181-1185.
8. Tezenas du Montcel S, Clot F, Vidailhet M, et al. Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet 2006;43:394-400.
9. Han F, Lang AE, Racacho L, Bulman DE, Grimes DA. Mutations in the epsilon-sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. Neurology 2003;61:244-246.
10. Grunewald A, Djarmati A, Lohmann-Hedrich K, et al. Myoclonus-dystonia: significance of large SGCE deletions. Human Mutat 2008;29:331-332.
11. Foncke EM, Gerrits MC, van Ruissen F, et al. Distal myoclonus and late onset in a large Dutch family with myoclonus-dystonia. Neurology 2006;67:1677-1680.
12. Raymond D, Saunders-Pullman R, de Carvalho Aguiar P, et al. Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. Mov Disord 2008;23:588-592.
13. Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology 2002;59: 1187-1196.
14. Nardocci N, Zorzi G, Barzaghi C, et al. Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord 2008;23:28-34.
15. Asmus F, Hjermind LE, Dupont E, et al. Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain 2007;130 (Pt 10):2736-2745.
16. Gerrits MC, Foncke EM, de Haan R, et al. Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia. Neurology 2006;66:759-761.
17. Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 1999;46:794-798.
18. Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol 2004;94:113-119.
19. Koukouni V, Valente EM, Cordivari C, Bhatia KP, Quinn NP. Unusual familial presentation of epsilon-sarcoglycan gene mutation with falls and writer's cramp. Mov Disord 2008;23: 1913-1915.
20. Hjermind LE, Werdelin LM, Eiberg H, Krag-Olsen B, Dupont E, Sorensen SA. A novel mutation in the epsilon-sarcoglycan gene causing myoclonus-dystonia syndrome. Neurology 2003; 60:1536-1539.
21. Vidailhet M, Tassin J, Durif F, et al. A major locus for several phenotypes of myoclonus-dystonia on chromosome 7q. Neurology 2001;56:1213-1216.
22. Gerrits MC, Foncke EM, Koelman JH, Tijssen MA. Pediatric writer's cramp in myoclonus-dystonia: Maternal imprinting hides positive family history. Eur J Paediatr Neurol (in press).
23. Hedrich K, Meyer EM, Schule B, et al. Myoclonus-dystonia: detection of novel, recurrent, and de novo SGCE mutations. Neurology 2004;62:1229-1231.
24. Borges V, Aguiar Pde C, Ferraz HB, Ozelius LJ. Novel and de novo mutations of the SGCE gene in Brazilian patients with myoclonus-dystonia. Mov Disord 2007;22:1208-1209.
25. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007;68:522-524.
26. Marechal L, Raux G, Dumanchin C, et al. Severe myoclonus-dystonia syndrome associated with a novel epsilon-sarcoglycan gene truncating mutation. Am J Med Genet B Neuropsychiatr Genet 2003;119:114-117.
27. Saunders-Pullman R, Shriberg J, Heiman G, et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 2002;58:242-245.
28. Misbahuddin A, Placzek M, Lennox G, Taanman JW, Warner TT. Myoclonus-dystonia syndrome with severe depression is caused by an exon-skipping mutation in the epsilon-sarcoglycan gene. Mov Disord 2007;22:1173-1175.
29. Asmus F, Zimprich A, Naumann M, et al. Inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families. Ann Neurol 2001;49:121-124.
30. Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-1586.
31. Jankovic J. Tourette's syndrome. N Engl J Med 2001;345: 1184-1192.
32. Foncke EM, Klein C, Koelman JH, et al. Hereditary myoclonus-dystonia associated with epilepsy. Neurology 2003;60: 1988-1990.
33. O'Riordan S, Ozelius LJ, de Carvalho Aguiar P, Hutchinson M, King M, Lynch T. Inherited myoclonus-dystonia and epilepsy: further evidence of an association? Mov Disord 2004; 19:1456-1459.
34. Kurlan R, Behr J, Medved L, Shoulson I. Myoclonus and dystonia: a family study. Adv Neurol 1988;50:385-389.
35. Borges V, Ferraz HB, de Andrade LA. Alcohol-sensitive hereditary essential myoclonus with dystonia: a study of 6 Brazilian patients. Neurol Sci 2000;21:373-377.
36. Trottenberg T, Meissner W, Kabus C, et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001;16:769-771.
37. Fahn S, Sjaastad O. Hereditary essential myoclonus in a large Norwegian family. Mov Disord 1991;6:237-247.
38. Mahloudji M, Pikielny RT. Hereditary essential myoclonus. Brain 1967;90:669-674.
39. Thobois S, Gervais-Bernard H, Xie-Brustolin J, Zyss J, Ostrowsky K, Broussolle E. Evidence for progressive changes in clinical presentation of myoclonus-dystonia. Mov Disord 2007;22: 1516-1517.
40. Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology 2002;59:1241-1243.
41. Kabakci K, Hedrich K, Leung JC, et al. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology 2004;62:395-400.
42. Chinnery PF, Reading PJ, McCarthy EL, Curtis A, Burn J. Late-onset axial jerky dystoniadue to the DYT1 deletion. Mov Disord 2002;17:196-198.
43. Asmus F, Devlin A, Munz M, Zimprich A, Gasser T, Chinnery PF. Clinical differentiation of genetically proven benign hereditary chorea and myoclonus-dystonia. Mov Disord 2007;22: 2104-2109.
44. Chung EJ, Lee WY, Kim JY, et al. Novel SGCE gene mutation in a Korean patient with myoclonus-dystonia with unique phenotype mimicking Moya-Moya disease. Mov Disord 2007;22: 1206-1207.
45. Chen XP, Zhang YW, Zhang SS, et al. A novel mutation of the epsilon-sarcoglycan gene in a Chinese family with myoclonus-dystonia syndrome. Mov Disord 2008;23:1472-1475
46. Korten JJ, Notermans SL, Frenken CW, Gabreels FJ, Joosten EM. Familial essential myoclonus. Brain 1974;97:131-138.
47. Li JY, Cunic DI, Paradiso G, et al. Electrophysiological features of myoclonus-dystonia. Mov Disord 2008;23:2055-2061.
48. Marelli C, Canafoglia L, Zibordi F, et al. A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord 2008;23:2041-2048.
49. Quinn NP, Rothwell JC, Thompson PD, Marsden CD. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol 1988;50:391-401.
50. Ettinger AJ, Feng G, Sanes JR. epsilon-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D. J Biol Chem 1997;272:32534-32538.
51. McNally EM, Ly CT, Kunkel LM. Human epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. FEBS Lett 1998;422: 27-32.
52. Hack AA, Groh ME, McNally EM. Sarcoglycans in muscular dystrophy. Microsc Res Tech 2000;48:167-180.
53. Hjermind LE, Vissing J, Asmus F, et al. No muscle involvement in myoclonus-dystonia caused by epsilon-sarcoglycan gene mutations. Eur J Neurol 2008;15:525-529.
54. Asmus F, Zimprich A, Tezenas Du Montcel S, et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002;52:489-492.
55. Straub V, Ettinger AJ, Durbeej M, et al. Epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J Biol Chem 1999;274: 27989-27996.
56. Nishiyama A, Endo T, Takeda S, Imamura M. Identification and characterization of epsilon-sarcoglycans in the central nervous system. Brain Res 2004;125:1-12.
57. Xiao J, LeDoux MS. Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan. Brain Res 2003; 119:132-143.
58. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, Sealfon SC. Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol 2005;482:50-73.
59. Muller B, Hedrich K, Kock N, et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 2002; 71:1303-1311.
60. Grabowski M, Zimprich A, Lorenz-Depiereux B, et al. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 2003;11: 138-144.
61. Monk D, Wagschal A, Arnaud P, et al. Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental-specific imprinted gene, TFPI2/Tfpi2, which requires G9a and Eed for allelic-silencing. Genome Res 2008;18:1270-1281.
62. DeBerardinis RJ, Conforto D, Russell K, et al. Myoclonus in a patient with a deletion of the epsilon-sarcoglycan locus on chromosome 7q21. Am J Med Genet 2003;121:31-36.
63. Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol 2005;58:792-797.
64. Valente EM, Misbahuddin A, Brancati F, et al. Analysis of the epsilon-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity. Mov Disord 2003;18:1047-1051.
65. Leung JC, Klein C, Friedman J, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 2001;3:133-143.
66. Klein C, Ozelius LJ. Dystonia: clinical features, genetics, and treatment. Curr Opin Neurol 2002;15:491-497.
67. Han F, Racacho L, Yang H, et al. Large deletions account for an increasing number of mutations in SGCE. Mov Disord 2008;23:456-460.
68. Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004;19:724-727.
69. Kock N, Kasten M, Schule B, et al. Clinical and genetic features of myoclonus-dystonia in 3 cases: a video presentation. Mov Disord 2004;19:231-234.
70. Schmickel RD. Contiguous gene syndromes: a component of recognizable syndromes. J Pediatr 1986;109:231-241.
71. Bonnet C, Gregoire MJ, Vibert M, Raffo E, Leheup B, Jonveaux P. Cryptic 7q21 and 9p23 deletions in a patient with apparently balanced de novo reciprocal translocation t(7;9) (q21;p23) associated with a dystonia-plus syndrome: paternal deletion of the epsilon-sarcoglycan (SGCE) gene. J Hum Genet 2008;53:876-885
72. Guettard E, Portnoi M, Lohmann-Hedrich K, et al. Myoclonus dystonia due to maternal uniparental disomy. Arch Neurol 2008;65:1380-1385.
73. Klein C, Brin MF, Kramer P, et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci USA 1999;96:5173-5176.
74. Durr A, Tassin J, Vidailhet M, et al. D2 dopamine receptor gene in myoclonic dystonia and essential myoclonus. Ann Neurol 2000;48:127-128.
75. Klein C, Liu L, Doheny D, et al. Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol 2002;52:675-679.
76. Doheny D, Danisi F, Smith C, et al. Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology 2002;59:1244-1246.
77. Grimes DA, Han F, Lang AE, St George-Hyssop P, Racacho L, Bulman DE. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology 2002;59:1183-1186.
78. Han F, Racacho L, Lang AE, Bulman DE, Grimes DA. Refinement of the DYT15 locus in myoclonus dystonia. Mov Disord 2007;22:888-892.
79. Yokoi F, Dang MT, Li J, Li Y. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan de.cient mice. J Biochem 2006;140: 141-146.
80. Beukers RJ, Booij J, Weisscher N, Zijlstra F, van Amelsvoort TA, Tijssen MA. Reduced striatal D receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging (in press).
81. Esapa CT, Waite A, Locke M, et al. SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 2007;16:327-342.
82. Meunier S, Lourenço G, Roze E, Apartis E, Trocello JM, Vidailhet M. Cortical excitability in DYT-11 positive myoclonus dystonia. Mov Disord 2008;23:761-764.
83. Nakamura TY, Iwata Y, Sampaolesi M, et al. Stretch-activated cation channels in skeletal muscle myotubes from sarcoglycan-deficient hamsters. Am J Physiol Cell Physiol 2001;281:C690-C699.
84. Foncke EM, Bour LJ, Speelman JD, Koelman JH, Tijssen MA. Local field potentials and oscillatory activity of the internal globus pallidus in myoclonus-dystonia. Mov Disord 2007;22: 369-376.
85. Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, Gomez-Galan M, Figueiras-Mendez R. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005;76:989-991.
86. Liu X, Griffin IC, Parkin SG, et al. Involvement of the medial pallidum in focal myoclonic dystonia: a clinical and neurophysiological case study. Mov Disord 2002;17:346-353.
87. Yianni J, Wang SY, Liu X, et al. A dominant bursting electromyograph pattern in dystonic conditions predicts an early response to pallidal stimulation. J Clin Neurosci 2006;13:738-746.
88. Nitschke MF, Erdmann C, Trillenberg P, et al. Functional MRI reveals activation of a subcortical network in a 5-year-old girl with genetically con.rmed myoclonus-dystonia. Neuropediatrics 2006;37:79-82.
89. Foncke EM, Bour LJ, van der Meer JN, Koelman JH, Tijssen MA. Abnormal low frequency drive in myoclonus-dystonia patients correlates with presence of dystonia. Mov Disord 2007;22:1299-1307.
90. Delecluse F, Waldemar G, Vestermark S, Paulson OB. Cerebral blood flow deficits in hereditary essential myoclonus. Arch Neurol 1992;49:179-182.
91. Papapetropoulos S, Argyriou AA, Polychronopoulos P, Spyridonidis T, Gourzis P, Chroni E. Frontotemporal and striatal SPECT abnormalities in myoclonus-dystonia: phenotypic and pathogenetic considerations. Neurodegenerative Dis 2008;5: 355-358
92. Zeuner KE, Molloy FM, Shoge RO, Goldstein SR, Wesley R, Hallett M. Effect of ethanol on the central oscillator in essential tremor. Mov Disord 2003;18:1280-1285.
93. Boecker H, Wills AJ, Ceballos-Baumann A, et al. The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol 1996;39:650-658.
94. Jia F, Chandra D, Homanics GE, Harrison NL. Ethanol modulates synaptic and extrasynaptic GABAA receptors in the thalamus. J Pharmacol Exp Ther 2008;326:475-482
95. Paradiso G, Cunic D, Saint-Cyr JA, et al. Involvement of human thalamus in the preparation of self-paced movement. Brain 2004;127 (Pt 12):2717-2731.
96. Gasser T. Inherited myoclonus-dystonia syndrome. Adv Neurol 1998;78:325-334.
97. Orth M, Djarmati A, Baumer T, et al. Autosomal dominant myoclonus-dystonia and Tourette syndrome in a family without linkage to the SGCE gene. Mov Disord 2007;22:2090-2096.
98. San Luciano M, Ozelius L, Raymond D, Liu L, Saunders-Pullman R. Responsiveness to levodopa in epsilon-sarcoglycan deletion. Neurology 2008;70(11 suppl 1):244.
99. Costa J, Borges A, Espirito-Santo C, et al. Botulinum toxin type A versus botulinum toxin type B for cervcal dystonia. Cochrane Database Syst Rev 2005;25:CD004314.
100. Costa J, Espirito-Santo C, Borges A, et al. Botulinum Toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005;25:CD003633.
101. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005; 25:CD004315.
102. Costa J, Espirito-Santo C, Borges A, Ferreira J, Coelho M, Sampaio C. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev 2005;25:CD004312.
103. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978-1990.
104. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352:459-467.